ArticleMicromachines2025
SlimPort: Port-Driven High-Level Synthesis for Continuous-Flow Microfluidic Biochips.
Article in Micromachines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Continuous-flow microfluidic biochips (CFMBs) automatically execute various bioassays by precisely controlling the transport of fluid samples, which is driven by pressure delivered through fluidic ports. High-level synthesis, as an important stage in the design flow of CFMBs, generates binding and scheduling solutions whose quality directly affects the efficiency of the execution of bioassays. Existing high-level synthesis methods perform numerous transport tasks concurrently to increase efficiency. However, fluidic ports cannot be shared between concurrently executing transport tasks, resulting in a large number of fluidic ports introduced by existing methods. Increasing the number of fluidic ports undermines the integration, reduces the reliability, and increases the manufacturing cost. In this paper, we propose a port-driven high-level synthesis method based on integer linear programming (ILP) called SlimPort, integrating the optimization of fluidic port number into high-level synthesis, which has never been considered in prior work. Meanwhile, to ensure bioassay correctness, volume management between devices with a non-fixed input/output ratio is realized. Additionally, two acceleration strategies for ILP, scheduling constraint reduction and upper boundary estimation of fluidic port number, are proposed to improve the efficiency of SlimPort. Experimental results from multiple benchmarks demonstrate that SlimPort leads to high assay execution efficiency and a low number of fluidic ports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.